Editor's Note The widespread adoption of GLP-1 weight-loss medications like Ozempic and Wegovy could put revenue at risk across multiple service lines, according to a March 11 article in Becker’s Hospital Review. As a result, hospitals and ambulatory surgery centers (ASCs) face critical questions about how to adapt. The article…